RCEL Shareholder Call Reiterates Reimbursement Headwinds, No New Catalysts

What happened

AVITA Medical held a shareholder/analyst call on August 12, 2026, reiterating that reimbursement changes in the first half of 2025 pressured demand for RECELL but that advocacy efforts should lead to recovery in the second half. The call did not appear to disclose new financial metrics or strategic pivots beyond previously reported cash of $12.2 million and interest outflows of $2.5 million. Management maintained its focus on driving adoption of the RECELL GO device and early commercialization of adjacent dermal matrices like Cohealyx. The company's installed base remains concentrated in U.S. burn centers, with utilization growth dependent on training and stable coding. The call offered no resolution to the key watch items of reimbursement stabilization and per-center procedure growth.

Implication

The call's content, while lacking new details, suggests management is staying the course on a recovery narrative that has yet to be validated by hard data. Near-term risk remains skewed to the downside given constrained cash and interest burden. However, the company's differentiated PMA-protected platform and optionality in reconstructive dermatology provide upside if adoption accelerates. We recommend monitoring quarterly procedure counts, cash runway, and any announcements on Cohealyx or international milestones. A move to BUY would require evidence of stabilizing reimbursement and improving per-center utilization; a move to SELL would be triggered by further liquidity deterioration or delayed recovery.

Thesis delta

The call does not materially alter our thesis; we maintain a HOLD/NEUTRAL stance. The report's key watch items—reimbursement stabilization, utilization growth, and liquidity—remain unresolved. Until those variables show concrete improvement, the risk/reward remains balanced.